KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short-term Investments (2016 - 2026)

Pacira BioSciences has reported Short-term Investments over the past 16 years, most recently at $57.9 million for Q1 2026.

  • For Q1 2026, Short-term Investments fell 72.44% year-over-year to $57.9 million; the TTM value through Mar 2026 reached $57.9 million, down 72.44%, while the annual FY2025 figure was $79.9 million, 61.57% down from the prior year.
  • Short-term Investments for Q1 2026 was $57.9 million at Pacira BioSciences, down from $79.9 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $225.4 million in Q1 2022 and troughed at $57.9 million in Q1 2026.
  • A 5-year average of $156.7 million and a median of $145.4 million in 2025 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: surged 160.5% in 2022 and later tumbled 72.44% in 2026.
  • Year by year, Short-term Investments stood at $184.5 million in 2022, then crashed by 32.1% to $125.3 million in 2023, then surged by 65.9% to $207.8 million in 2024, then crashed by 61.57% to $79.9 million in 2025, then decreased by 27.55% to $57.9 million in 2026.
  • Business Quant data shows Short-term Investments for PCRX at $57.9 million in Q1 2026, $79.9 million in Q4 2025, and $98.7 million in Q3 2025.